Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results

Blood Adv (2024) 8 (6): 1515–1528.

https://doi.org/10.1182/bloodadvances.2023011620

Published: 2024

Includes: Supplemental data

Journal Articles

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models

Mary Figueroa, Huaxian Ma, Mansour Alfayez, Daniel Enrique Morales-Mantilla, Fei Wang, Yue Lu, Marcos R. Estecio, Katherine Y. King, Eugenie Kleinerman, Seyed Javad Moghaddam, Naval Daver, Michael Andreeff, Marina Konopleva, Courtney DiNardo, Joya Chandra

Blood Adv (2023) 7 (21): 6624–6629.

https://doi.org/10.1182/bloodadvances.2023010111

Published: 2023

Includes: Supplemental data

Journal Articles

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Blood Adv (2023) 7 (14): 3573–3581.

https://doi.org/10.1182/bloodadvances.2022009632

Published: 2023

Includes: Supplemental data

Journal Articles

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Blood Adv (2023) 7 (13): 3284–3296.

https://doi.org/10.1182/bloodadvances.2022009391

Published: 2023

Includes: Supplemental data

Journal Articles

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2 -mutant myelodysplastic syndrome

Blood Adv (2023) 7 (11): 2378–2387.

https://doi.org/10.1182/bloodadvances.2022008378

Published: 2023

Includes: Supplemental data

Journal Articles

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Blood Adv (2023) 7 (10): 1958–1966.

https://doi.org/10.1182/bloodadvances.2022008790

Published: 2023

Includes: Supplemental data

Journal Articles

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Adv (2023) 7 (6): 933–942.

https://doi.org/10.1182/bloodadvances.2022008316

Published: 2023

Includes: Supplemental data

Journal Articles

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

Hussein A. Abbas, Hanxiao Sun, Sherry Pierce, Rashmi Kanagal-Shamanna, Ziyi Li, Musa Yilmaz, Gautam Borthakur, Adam J. DiPippo, Elias Jabbour, Marina Konopleva, Nicholas J. Short, Courtney DiNardo, Naval Daver, Farhad Ravandi, Tapan M. Kadia

Blood Adv (2023) 7 (5): 828–831.

https://doi.org/10.1182/bloodadvances.2022007172

Published: 2023

Includes: Supplemental data

Journal Articles

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

Sangeetha Venugopal, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, Nicholas J. Short, Hussein A. Abbas, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi, Tapan M. Kadia

Blood Adv (2022) 6 (19): 5546–5549.

https://doi.org/10.1182/bloodadvances.2021006689

Published: 2022

Journal Articles

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Blood Adv (2022) 6 (13): 4006–4014.

https://doi.org/10.1182/bloodadvances.2022007378

Published: 2022

Includes: Supplemental data

Journal Articles

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

Naveen Pemmaraju, Nathaniel R. Wilson, Guillermo Garcia-Manero, Koji Sasaki, Joseph D. Khoury, Nitin Jain, Gautam Borthakur, Farhad Ravandi, Naval Daver, Tapan Kadia, Courtney DiNardo, Elias Jabbour, Sherry Pierce, Muzaffar Qazilbash, Marina Konopleva, Hagop Kantarjian

Blood Adv (2022) 6 (10): 3027–3035.

https://doi.org/10.1182/bloodadvances.2021006645

Published: 2022

Includes: Supplemental data

Journal Articles

Gilteritinib combination therapies in pediatric patients with FLT3 -mutated acute myeloid leukemia

David McCall, Michael Roth, Kris M. Mahadeo, Laurie Toepfer, Cesar Nunez, Nicholas J. Short, Naval Daver, Tapan M. Kadia, Courtney DiNardo, Joanna S. Yi, Branko Cuglievan

Blood Adv (2021) 5 (23): 5215–5219.

https://doi.org/10.1182/bloodadvances.2021005164

Published: 2021

Journal Articles

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy

Hussein A. Abbas, Zoe Alaniz, Sean Mackay, Matthew Cyr, Jing Zhou, Ghayas C. Issa, Mansour Alfayez, Jairo Matthews, Steven M. Kornblau, Elias Jabbour, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Naval Daver

Blood Adv (2021) 5 (22): 4569–4574.

https://doi.org/10.1182/bloodadvances.2021004583

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Blood Adv (2021) 5 (8): 2173–2183.

https://doi.org/10.1182/bloodadvances.2020004173

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML

Nicholas J. Short, Hind Rafei, Naval Daver, Hyunsoo Hwang, Jing Ning, Jeffrey L. Jorgensen, Tapan M. Kadia, Courtney D. DiNardo, Sa A. Wang, Elias Jabbour, Uday Popat, Betul Oran, Jorge Cortes, Marina Konopleva, Musa Yilmaz, Ghayas C. Issa, Hagop Kantarjian, Farhad Ravandi

Blood Adv (2020) 4 (24): 6117–6126.

https://doi.org/10.1182/bloodadvances.2020002811

Published: 2020

Includes: Supplemental data

Journal Articles

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Nicholas J. Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, Jing Ning, Miguel J. Franquiz, Rashmi Kanagal-Shamanna, Keyur P. Patel, Courtney D. DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Koichi Takahashi, Marina Konopleva, Naval Daver, Ghayas C. Issa, Michael Andreeff, Hagop Kantarjian, Tapan M. Kadia

Blood Adv (2020) 4 (22): 5681–5689.

https://doi.org/10.1182/bloodadvances.2020003120

Published: 2020

Includes: Supplemental data

Journal Articles

Outcome of patients with IDH1/2- mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Helen T. Chifotides, Lucia Masarova, Mansour Alfayez, Naval Daver, Yesid Alvarado, Elias Jabbour, Marina Konopleva, Hagop M. Kantarjian, Keyur P. Patel, Courtney D. DiNardo, Srdan Verstovsek

Blood Adv (2020) 4 (21): 5336–5342.

https://doi.org/10.1182/bloodadvances.2020001528

Published: 2020

Journal Articles

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Blood Adv (2020) 4 (7): 1311–1320.

https://doi.org/10.1182/bloodadvances.2019001267

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Blood Adv (2020) 4 (3): 482–495.

https://doi.org/10.1182/bloodadvances.2019001101

Published: 2020

Includes: Supplemental data

Journal Articles

Co-occurrence of FLT3 -TKD and NPM1 mutations defines a highly favorable prognostic AML group

Prajwal Boddu, Hagop Kantarjian, Gautam Borthakur, Tapan Kadia, Naval Daver, Sherry Pierce, Michael Andreeff, Farhad Ravandi, Jorge Cortes, Steven M. Kornblau

Blood Adv (2017) 1 (19): 1546–1550.

https://doi.org/10.1182/bloodadvances.2017009019

Published: 2017

Includes: Supplemental data

NARROW

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2 -mutant myelodysplastic syndrome

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

Gilteritinib combination therapies in pediatric patients with FLT3 -mutated acute myeloid leukemia

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Outcome of patients with IDH1/2- mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Co-occurrence of FLT3 -TKD and NPM1 mutations defines a highly favorable prognostic AML group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only